Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. · 2021
Read Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. by Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7782714.txt.
Introduction
Schettini and co-authors examine HER2-low breast cancer, a group now targeted by new antibody-drug conjugates. These cancers show low HER2 levels but no ERBB2 amplification. The team gathered clinical, pathology, and PAM50 gene data. Their sample covered 3,689 patients with HER2-negative disease.
HER2-low tumors made up 65.4% of hormone receptor-positive cases. In triple-negative disease the share was 36.6%. Within hormone receptor-positive disease, HER2-low tumors expressed more ERBB2 and luminal genes than HER2 0 tumors. No gene split the triple-negative group by HER2 level. HER2-low status did not track with overall survival. Scoring of low HER2 by pathologists agreed poorly. The authors call for more reliable tests for low HER2 levels.
Catalog record
| CREATOR | Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer By Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre Published in: NPJ Breast Cancer DOI: 10.1038/s41523-020-00208-2 ABSTRACT Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression. INTRODUCTION HER2-positive breast cancer is currently defined according to the ASCO/CAP guidelines using immunohistochemistry (IHC) and/or in situ hybridization (ISH)-based techniques1,2. These guidelines identify a tumor as HER2-positive when there is a complete and intense circumferential HER2 IHC staining in ≥10% of cells (score 3+) and/or the gene is amplified with an HER2/CEP17 ratio ≥2.0 and an average HER2 gene (ERBB2) copy number ≥4.0 signals/cell using ISH-based techniques1. In breast cancer, 10–20% of tumors are HER2-positive and 80–90% are HER2-negative3,4. Within HER2-negative disease, substantial heterogeneity exists regarding the expression of hormone receptors (HR) and HER2. For example, HER2-negative tumors can express some protein level of HER2 by IHC5 (i.e., 1+ or 2+ and lack of ERBB2 amplification by in situ hybridization techniques) and are identified as HER2-low. Traditionally, patients with HER2-low-expressing tumors do not seem to benefit from HER2-targeted therapies, such as 1-year of adjuvant trastuzumab6. However, two HER2-directed antibody-drug conjugates (ADC) with chemotherapeutics, namely trastuzumab deruxtecan (T-DXd) and trastuzumab duocarmazine (SYD985) have shown very promising therapeutic activity in patients with HER2-low breast cancer7–9. A large pivotal randomized phase III trial of T-DXd in patients with pretreated HER2-low metastatic breast cancer is underway (i.e., NCT03734029/DESTINY-Breast04). Owing to the recent and increased interest in the HER2-low group, there is an urgent need to better understand its clinicopathological and molecular features. Thus, we decided to collect clinicopathological and PAM50 gene expression data from multiple datasets10–17 of HER2-negative disease and compare many features between HER2-low and HER2 0. Analyses were focused on the overall population and according to hormone receptor (HR) status and HER2 IHC expression. RESULTS Clinicopathological characteristics of HER2-low disease Thirteen independent datasets for a total of 3,689 patients with HER2-negative breast cancer were explored (Fig. 1). Overall, 1,486 (40.3%) patients had HER2 0 tumors, 1,489 (40.4%) had HER2 1+ tumors and 714 (19.3%) had HER2 2+ tumors. Clinicopathological and gene expression data (when available) were largely obtained from primary disease (71.1% in HER2-low and 73.7% in HER2 0). According to HR status, 2,962 (80.8%) patients had HR-positive disease and 706 (19.2%) had triple-negative breast cancer (TNBC).Fig. 1STROBE flow-chart.Flow-chart resuming the patient selection process, showing causes for exclusion and the number of patients with available data for the main analyses presented in the study. GEICAM Grupo Español de Investigación en Cáncer de Mama, CIBOMA Coalición Iberoamericana de Investigación en Oncología Mamaria, VHIO Vall d’Hebron Institute of Oncology, SOLTI Solid Tumor Intensification Group, IHC immunohistochemistry, ISH in-situ hybridization, HR hormone receptors. HER2-low tumors were more frequently found within HR-positive disease compared to TNBC (65.4% vs. 36.5%, p < 0.001; Fig. 2). More specifically, HR-positive disease was characterized by higher rates of IHC 1+ and 2+ tumors, compared to TNBC (43.8% vs. 26.8% and 21.6% vs. 9.8%, respectively, p < 0.001; Fig. 2). In terms of other clinicopathological variables, HER2-low tumors presented larger primary tumor sizes (p = 0.007) and more nodal involvement (p = 0.010) compared to HER2 0 tumors (Table 1 and Supplementary Table 1). No male patient was observed within the HER2 0 cohort, compared to the 15 cases observed in the HER2-low subset (p = 0.001). The median age at diagnosis was higher for the HER2-low tumors compared to HER2 0 (59 vs. 55 years, p = 0.003). No statistically significant differences were observed in terms of menopausal status (p = 0.898), histological grade (p = 0.175), Ki67 IHC scores (p = 0.092 using a 14% cut-off) and percentage of stromal tumor-infiltrating lymphocytes (TILs) (p = 0.218), although TILs’ levels were differently distributed according to HER2 IHC levels (p = 0.033) and were higher in HER2 2+ (median: 5; interquartile range [IQR] 1–5) compared to 1+ (median: 1; IQR 1–5; p = 0.035) and 0 (median: 1; IQR 1–5; p = 0.035).Fig. 2Hormone receptor status, HER2-low status, and IHC scores distributions within the HER2-negative population.HR hormone receptors, IHC immunohistochemistry, ISH in situ hybridization (including either FISH, SISH, and CISH).Table 1Population characteristics according to HER2 status.DemographicsHER2-negativepaHER2 0HER2-lowOverall populationN%N%N%1,48640.32,20359.73,689100Age at diagnosis (years) Median5559580.003 IQR46–6549–6748–67 Min–max24–9326–9624–96 Pts with available data25927.468572.6944100Sex Male00150.7150.40.001 Female1,4861002,18799.33,67399.6 Total1,48640.32,20259.73,688100Menopaual status Pre/perimenopausal38537.366037.11,04537.20.898 Postmenopausal64662.71,11962.91,76562.8 Total1,03136.71,77963.32,810100Biospecimen Primary lesion1,00073.71,38271.12,38272.10.096 Other lesion35734.656328.992027.9 Total1,35741.11,94558.93,302100Histotype Ductal63970.81,21474.31,853730.175 Lobular19421.531419.250820 Other697.61076.51766.9 Total90235.61,63564.42,537100T 150955.880748.71,31651.20.007 229432.261837.391235.5 3717.81428.62138.3 4384.2895.41274.9 Total91235.51,65664.52,568100N 055658.893755.61,49356.80.01 127228.846427.673628 2717.51488.82198.3 3464.913581816.9 Total94535.91,68464.12,629100ER Positive983671,89487.12,87779<0.001 Negative4843328012.976421 Total1,46740.32,17459.73,641100PgR Positive78954.71,54271.82,33164.9<0.001 Negative65445.360628.2126035.1 Total1,44340.22,14859.83,591100G 1678.813910.62069.90.0499 227235.651439.178637.8 342655.766050.3108652.3 Total76536.81,31363.22,078100Ki67 Median1618180.892 IQR9–3010–2710–27 Min–max0.5–950.5–950.5–95 Pts with available data43336.475663.61,189100 ≤14%19043.929438.948440.70.092 >14%24356.146261.170559.3 <20%23654.541154.464754.40.963 ≥20%19745.534545.654245.6TILs Median1110.218 IQR0–51–51–5 Min–max0–800–800–80 Pts with available data10237.217262.8274100PAM50 subtypes Luminal A19328.745950.865241.4<0.001 Luminal B12718.926028.838724.6 HER2-enriched405.9323.5724.6 Basal-like29443.712013.341426.3 Normal-like192.8323.5513.1 Total67342.790357.31,576100HR status HR-positive1,02569.61,93788.22,96280.8<0.001 TNBC44830.425811.870619.2 Total1,47340.2219559.83,668100aChi-square test for differences in proportions, Kruskalis–Wallis and Wilcoxon rank sum test with continuity correction, where appropriate, for continuous variables (median comparisons).Pts patients, HR hormone receptors, IQR interquartile range, IHC immunohistochemical, TILs tumor-infiltrating lymphocytes. Reproducibility of the HER2-low classification To evaluate the reproducibility of HER2 IHC scoring among pathologists, we scanned 200 HER2 IHC stained slides from 100 independent cases of the Hospital Clinic case series. The images were representative of the 4 HER2 IHC categories (i.e., 0, 1+, 2+ and 3+). Five breast cancer-specialized pathologists (BG, ES, RF, GP, and VP), coming from four different institutions (Clinic, VHIO, VHV, and Campus Bio-Medico), revised and scored the 100 cases in a blinded fashion. Overall, 35 discordant cases (35%) were observed. The discordances were between IHC 1+ vs. 0 (n = 15), 1+ vs. 2+ (n = 12), 2+ vs. 0 (n = 1), 3+ vs. 1 + (n = 1), and 3+ vs. 2+ (n = 6) scores. In most cases (25 of 35, 71.4%), only one pathologist was discordant with the others. The multi-rater overall kappa concordance score was 0.79 (p < 0.001), which is considered a substantial agreement. The kappa scores according to the HER2 IHC categories 0, 1+, 2+, and 3+ were 0.82 (almost perfect agreement), 0.67 (substantial agreement), 0.74 (substantial agreement) and 0.92 (almost perfect agreement), respectively (p < 0.001). Similar results were obtained when the HER2 3+ cases were removed (data not shown). Distribution of the PAM50 intrinsic subtypes PAM50 intrinsic subtypes were available from 1,576 (42.7%) patients. Intrinsic subtypes were differentially distributed